Menu
Search
|

Menu

Close
X

Aurinia Pharmaceuticals Inc AUPH.OQ (NASDAQ Stock Exchange Global Market)

5.22 USD
-0.07 (-1.32%)
As of Feb 16
chart
Previous Close 5.29
Open 5.28
Volume 48,683
3m Avg Volume 213,745
Today’s High 5.32
Today’s Low 5.22
52 Week High 10.54
52 Week Low 3.23
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.71 Mean rating from 7 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Richard Glickman
Executive Chairman of the Board, Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Dennis Bourgeault
Chief Financial Officer, Corporate Secretary, Since 2011
Salary: $228,333.00
Bonus: $150,000.00
Michael Martin
Chief Operating Officer, Since 2014
Salary: $269,167.00
Bonus: $135,626.00
Neil Solomons
Chief Marketing Officer, Since 2013
Salary: $310,000.00
Bonus: $149,250.00
Celia Economides
Associate Vice President, Corporate Communications & Patient Advocacy, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1203-4464 Markham St
VICTORIA   BC   V8Z 7X8

Phone: +1250.7084272

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

SPONSORED STORIES